The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Novel classes of antibiotics or more of the same?
Open accessAbstract
The world is running out of antibiotics. Between 1940 and 1962, more than 20 new classes of antibiotics were marketed. Since then, only two new classes have reached the market. Analogue development kept pace with the emergence of resistant bacteria until 10–20 years ago. Now, not enough analogues are reaching the market to stem the tide of antibiotic resistance, particularly among gram‐negative bacteria. This review examines the existing systemic antibiotic pipeline in the public domain, and reveals that 27 compounds are in clinical development, of which two are new classes, both of which are in Phase I clinical trials. In view of the high attrition rate of drugs in early clinical development, particularly new classes and the current regulatory hurdles, it does not seem likely that new classes will be marketed soon. This paper suggests that, if the world is to return to a situation in which there are enough antibiotics to cope with the inevitable ongoing emergence of bacterial resistance, we need to recreate the prolific antibiotic discovery period between 1940 and 1962, which produced 20 classes that served the world well for 60 years. If another 20 classes and their analogues, particularly targeting gram‐negatives could be produced soon, they might last us for the next 60 years. How can this be achieved? Only a huge effort by governments in the form of finance, legislation and providing industry with real incentives will reverse this. Industry needs to re‐enter the market on a much larger scale, and academia should rebuild its antibiotic discovery infrastructure to support this effort. The alternative is Medicine without effective antibiotics. LINKED ARTICLES This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue‐1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718 · cited 1×
“…some strains of Neisseria meningitidis (du Plessis et al., 2008) still show only a reduced susceptibility to penicillin, while for S. aureus (Chambers and Deleo, 2009) resistance to penicillin appeared in the early 1940s, shortly after its introduction into the market, and resistance to…”
BackgroundDrugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 1×
“In addition, the genomics approach (Payne et al., 2007) in which essential enzyme pathways in bacteria are targeted by inhibitors, may provide new classes, although none have been marketed so far.”
BackgroundMechanisms of Antimicrobial Resistance in Bacteria
Tenover, F. C. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.011 · Cited by 1,682
Fleming, A. (1929) · PubMed Central · Cited by 1,647
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
Klein, E., Smith, D. L., & Laxminarayan, R. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1312.070629 · Cited by 862
Type IIA topoisomerase inhibition by a new class of antibacterial agents
Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., et al. (2010) · Nature · doi:10.1038/nature09197 · Cited by 860
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Self-citationMechanisms of antimicrobial resistance in bacteria
Tenover, F. C. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.219 · Cited by 637
The Evolution of Class 1 Integrons and the Rise of Antibiotic Resistance
Gillings, M., Boucher, Y., Labbate, M., Holmes, A., Krishnan, S., Holley, M., & Stokes, H. W. (2008) · Journal of Bacteriology · doi:10.1128/jb.00152-08 · Cited by 495
The biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
Measuring the global burden of disease and epidemiological transitions: 2002–2030
Lopez, A. D., & Mathers, C. D. (2006) · Annals of Tropical Medicine & Parasitology · doi:10.1179/136485906x97417 · Cited by 462
Bacterial resistance to antibiotics: Modified target sites
LAMBERT, P. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.003 · Cited by 424
Progress and Challenges in Implementing the Research on ESKAPE Pathogens
Rice, L. B. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/655995 · Cited by 370
Natural products — The future scaffolds for novel antibiotics?
Butler, M. S., & Buss, A. D. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.012 · Cited by 337
Robust Salmonella metabolism limits possibilities for new antimicrobials
Becker, D., Selbach, M., Rollenhagen, C., Ballmaier, M., Meyer, T. F., Mann, M., & Bumann, D. (2006) · Nature · doi:10.1038/nature04616 · Cited by 335
The soil metagenome – a rich resource for the discovery of novel natural products
Daniel, R. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.04.005 · Cited by 334
RIEDLINGER, J., REICKE, A., ZÄHNER, H., KRISMER, B., BULL, A. T., MALDONADO, L. A., WARD, A. C., GOODFELLOW, M., BISTER, B., BISCHOFF, D., et al. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.271 · Cited by 296
Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1581-1585.2006 · Cited by 262
A Modern Look at Folkloric Use of Anti-infective Agents
Mitscher, L. A., Drake, S., Gollapudi, S. R., & Okwute, S. K. (1987) · Journal of Natural Products · doi:10.1021/np50054a003 · Cited by 256
Antibacterial discovery and development—the failure of success?
Fernandes, P. (2006) · Nature Biotechnology · doi:10.1038/nbt1206-1497 · Cited by 246
Snake Cathelicidin from Bungarus fasciatus Is a Potent Peptide Antibiotics
Wang, Y., Hong, J., Liu, X., Yang, H., Liu, R., Wu, J., Wang, A., Lin, D., & Lai, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003217 · Cited by 246
Empirical antibacterial drug discovery—Foundation in natural products
Singh, S. B., & Barrett, J. F. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.016 · Cited by 245
Antimicrobial drug development – the past, the present, and the future
Powers, J. H. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1007.x · Cited by 224
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Mitchison, D. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1603oe · Cited by 185
Prevalence of Livestock-Associated MRSA in Communities with High Pig-Densities in The Netherlands
van Cleef, B. A. G. L., Verkade, E. J. M., Wulf, M. W. H., Buiting, A. G. M., Voß, A., Huijsdens, X. W., van Pelt, W., Mulders, M. N., & Kluytmans, J. A. J. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009385 · Cited by 170
Newer antibacterial drugs for a new century
Devasahayam, G., Scheld, W. M., & Hoffman, P. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903505092 · Cited by 155
Brogden, R. N., Carmine, A., Heel, R. C., Morley, P. A., Speight, T. M., & Avery, G. S. (1981) · Drugs · doi:10.2165/00003495-198122050-00001 · Cited by 131
Walkey, A. J., O’Donnell, M. R., & Wiener, R. S. (2010) · CHEST Journal · doi:10.1378/chest.10-1556 · Cited by 126
Flores-Villaseñor, H. M., Canizalez‐Román, A., Reyes‐López, M., Nazmi, K., de la Garza, M., Zazueta-Beltrán, J., León-Sicairos, N. M., & Bolscher, J. G. M. (2010) · BioMetals · doi:10.1007/s10534-010-9306-4 · Cited by 121
The SOS response promotes qnrB quinolone‐resistance determinant expression
Re, S. D., Garnier, F., Guérin, É., Campoy, S., Denis, F., & Ploy, M. C. (2009) · EMBO Reports · doi:10.1038/embor.2009.99 · Cited by 107
Postgenomic Strategies in Antibacterial Drug Discovery
Brötz‐Oesterhelt, H., & Saß, P. (2010) · Future Microbiology · doi:10.2217/fmb.10.119 · Cited by 105
Hair, P. I., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767100-00008 · Cited by 90
Tackling antibiotic resistance
So, A. D., Gupta, N., & Cars, O. (2010) · BMJ · doi:10.1136/bmj.c2071 · Cited by 86
Targeting non-multiplying organisms as a way to develop novel antimicrobials
Coates, A. R. M., & Hu, Y. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.12.001 · Cited by 84
Self-citationAntibiotic resistance - what can we do?
Bax, R. P., Anderson, R. M., Crew, J., Fletcher, P. S., Johnson, T., Kaplan, E. L., Knaus, B., Kristinsson, K. G., Malek, M., & Strandberg, L. (1998) · Nature Medicine · doi:10.1038/nm0598-545 · Cited by 84
Hu, Y., Shamaei‐Tousi, A., Liu, Y., & Coates, A. R. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011818 · Cited by 80
Self-citationZappia, G., Menéndez, P., Monache, G. D., Misiti, D., Nevola, L., & Botta, B. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707780363783 · Cited by 76
Falagas, M. E., Bliziotis, I. A., & Fragoulis, K. N. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.09.005 · Cited by 74
Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections
Zhanel, G. G., Trapp, S., Gin, A. S., DeCorby, M. R., Lagacé-Wiens, P. R. S., Rubinstein, E., Hoban, D. J., & Karlowsky, J. A. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.1.67 · Cited by 63
du Plessis, M., von Gottberg, A., Cohen, C., de Gouveia, L., & Klugman, K. P. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00221-08 · Cited by 39
Cited by
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Self-citationAntibiotic resistance: a rundown of a global crisis
Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., Nisar, M. A., Alvi, R. F., Aslam, M. A., Qamar, M. U., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173867 · Cited by 2,552
Metal-Based Nanoparticles as Antimicrobial Agents: An Overview
Sánchez-López, E., Gomes, D., Esteruelas, G., Bonilla, L., Lopez-Machado, A. L., Galindo, R., Cano, A., Espina, M., Ettcheto, M., Camins, A., et al. (2020) · Nanomaterials · doi:10.3390/nano10020292 · Cited by 1,474
“However, a high number of analogues of existing classes and antibiotic combinations has reached the market [2].”
BackgroundAntibiotics in the aquatic environments: A review of the European scenario
Carvalho, I. T., & Santos, L. (2016) · Environment International · doi:10.1016/j.envint.2016.06.025 · Cited by 1,324
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Metadata
- Authors
- Coates, A. R., Halls, G., & Hu, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-04-06
- Volume
- 163
- Issue
- 1
- Pages
- 184-194
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1502497970
- Cited by
- 598
- References
- 44
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.